Current advances and future visions on bioelectronic immunosensing for prostate-specific antigen

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Diagnostics

Background:

• Current prostate cancer (PCa) diagnostics face limitations in early detection, portability, and rapid feedback.
• Label-free biosensing devices, particularly electronic immunosensors, offer inherent advantages for sensitive and specific biomarker detection.
• Antigen-antibody interactions form the basis for high-performance bioelectronic immunosensors.

Purpose of the Study:

• To review recent advancements in bioelectronic immunosensors for prostate cancer biomarker detection over the past decade.
• To highlight research milestones and current trends in the development of these devices.
• To project future directions for the clinical translation of bioelectronic immunosensors for PCa.

Main Methods:

• Review of literature on bioelectronic immunosensors for PCa detection published in the last 10 years.
• Analysis of research trends, including sensitivity, specificity, and detection platforms.
• Exploration of miniaturization and point-of-care potential.

Main Results:

• Bioelectronic immunosensors demonstrate high sensitivity and specificity for PCa biomarkers.
• These devices offer rapid detection, ease of preparation, and potential for miniaturization.
• Significant progress has been made in developing various bioelectronic immunosensing platforms for PCa.

Conclusions:

• Bioelectronic immunosensors represent a significant advancement in early prostate cancer diagnosis.
• Continued research and development are essential for overcoming challenges in clinical implementation.
• The future vision points towards "lab-to-market" realization for improved PCa management.